ThomasJKippsMD

Oncology • La Jolla, CA

Professor of Medicine, UCSD

Join to view full profile

Dr. Kipps is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kipps' full profile

Already have an account?

Office
3855 Health Sciences Dr
# Mail
La Jolla, CA 92093
Phone+1 858-534-5400

Fax+1 858-534-5620

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 1982 - 1984
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1979 - 1981
Harvard Medical SchoolClass of 1979

Certifications & Licensure

CA State Medical License 1980 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2010-2014
Top Doctors:San Diego Area Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2009-2013
Top Doctors:Southern California Castle Connolly, 2012
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Elected Member The American Society for Clinical Investigation, 1991
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2006 Jan 01
Completed
Phase 2
A Study to Evaluate the Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) Start of enrollment: 2006 Mar 01
Terminated
Phase 1, Phase 2
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2008 Feb 01
Unknown status
Phase 2
Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy Start of enrollment: 2003 Dec 01
Unknown status
Phase 2
Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Start of enrollment: 2009 Jan 01
Terminated
Phase 2
Study of Repeat Intranodal Injections of Ad-ISF35 Start of enrollment: 2009 Jun 01
Terminated
Phase 2
A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia Start of enrollment: 2009 May 01
Terminated
Phase 1, Phase 2
A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) Start of enrollment: 2009 Sep 01
Terminated
Phase 1
Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2010 Aug 01
Completed
Phase 2
Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2010 Aug 01
Completed
Phase 2
Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2011 Dec 01
Terminated
Phase 2
Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia Start of enrollment: 2011 Nov 01
Terminated
Phase 2
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Feb 05
Terminated
Phase 3
Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome Start of enrollment: 2017 Dec 20
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

4 citations
Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia.
Richard L Wong, Michael Y Choi, Huan-You Wang, Thomas J Kipps
Leukemia. 2024-08-01
Variant Transcript of ROR1 ENST00000545203 Does Not Encode ROR1 Protein.
Jie Xian, Navyaa Sinha, Christina Girgis, Christopher S Oh, Matthew R Cring
Biomedicines. 2024-07-16
Aberrant spliceosome activity via elevated intron retention and upregulation and phosphorylation of SF3B1 in chronic lymphocytic leukemia.
Manoj Kumar Kashyap, Hiren Karathia, Deepak Kumar, Roberto Vera Alvarez, Jose Vicente Forero-Forero
Molecular Therapy. Nucleic Acids. 2024-06-11

Journal Articles

SET Alpha and SET Beta mRNA Isoforms in Chronic Lymphocytic Leukaemia
Danielle M Brander, J Brice Weinberg, Daphne R Friedman, Thomas J Kipps, British Journal of Haematology
Sustained Efficacy and Detailed Clinical Follow-up of First-Line Ibrutinib Treatment in Older Patients with Chronic Lymphocytic Leukemia: Extended Phase 3 Results from...
Steven Coutre, Thomas J Kipps, Jan A Burger, Nancy L Bartlett, Paul M Barr, Haematologica
MiR-125a and MiR-34a Expression Predicts Richter Syndrome in Chronic Lymphocytic Leukemia Patients
Thomas J Kipps, John A Thorson, Blood

Abstracts/Posters

Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
Thomas J. Kipps, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisoc...
Thomas J. Kipps, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
High-Level ROR1 and BCL2, Cancer-Stemness, and BCL2 Mutations Associate with Venetoclax Resistance in Chronic Lymphocytic Leukemia
Thomas J. Kipps, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...
Thomas J. Kipps, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients ...
Thomas J. Kipps, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...
Thomas J. Kipps, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Wnt5a Induces ROR1-Dependent Upregulation of MMP9 and Enhanced Invasiveness in Chronic Lymphocytic Leukemia
Thomas J. Kipps, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL
Thomas J. Kipps, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R...
Thomas J. Kipps, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of t...
Thomas J. Kipps, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Approaches to Personalized Treatment for CLL: Expert Guidance on Sequencing Therapy and Novel Agents
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Ibrutinib Reduces Obinutuzumab-Gazyva Infusion Related Reactions (IRR) in Patients with Chronic Lymphocytic Leukemia (CLL) and It Is Associated with Changes on Plasma ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Durability of Responses on Continuous Therapy and Following Drug Cessation in Deep Responders with Venetoclax and Rituximab
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Wnt5a Induces Association of ROR1 with Ca2+/Calmodulin-Dependent Protein Kinase II and ROR1-Dependent Calcium Influx in Chronic Lymphocytic Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Development of Cirmtuzumab Antibody-Drug Conjugates (ADCs) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
ROR1 Expression Is Associated with Oncogenic Dedifferentiation in Chronic Lymphocytic Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

Scientists Map Genetic Evolution of Chronic Lymphocytic Leukemia to Richter’s SyndromeDecember 11th, 2022
What's on Tap at the Society of Hematologic Oncology's 10th Annual MeetingSeptember 26th, 2022
Oncternal Therapeutics : Lee 2022 ASCO Poster Zilovertamab + Ibrutinib for MCL and CLLJune 7th, 2022
Join now to see all

Grant Support

Specialized Cancer Center Support GrantNational Cancer Institute2011
Chronic Lymphocytic Leukemia Research ConsortiumNational Cancer Institute2000–2011
Antibody V Gene Expression B Cell Lymphocytic LeukemiaNational Cancer Institute1999–2011
Lenalidomide Treatment And The Chronic Lymphocytic Leukemia MicroenvironmentNational Cancer Institute2009–2010
Active Immune Therapy OT Leukemia Associated Antigens And Gene TherapyNational Cancer Institute2006–2010
Tumor Therapy/Annihilation Using A Smart Nanoplatform (SNAP)National Cancer Institute2005–2009
A CRC Phase 1 Study Of Clofarabine For Treatment Of Relapsed/Refractory CLLNational Center For Research Resources2006
Administrative CoreNational Cancer Institute2006
Phase I/II Study Of Xcellerated T Cells In Chronic Lymphocytic LeukemiaNational Center For Research Resources2005–2006
Immune Monitoring In B Cell CLL Patients Treated With Ad-Cd154 CellsNational Center For Research Resources2005
Gx15-070ms Every 3 Weeks For Refractory Chronic Lymphocytic LeukemiaNational Center For Research Resources2005
Phase I/II Study Of Xcellerated T Cells In CLLNational Center For Research Resources2004
Immune Monitoring In B Cell CLL Treated With Ad-Cd154National Center For Research Resources2004
Competing Supplement For CLL Research ConsortiumNational Cancer Institute2003
Translational OncologyNational Cancer Institute2001–2002
Gene Transfer Of CD154 Into Myeloma Plasma CellsNational Center For Research Resources2000–2002
Autoimmune Hemolytic Anemia And Expression Of IG GenesNational Center For Research Resources2000–2002
Immunology Of CLL I--Acitive ImmunotherapyNational Cancer Institute2000–2002
Phase I Study Of CD40 Ligand Transduced Leukemia Cells In CLLNational Center For Research Resources1999–2002
Synovium As An Immune Underprivileged SiteNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1998–2002
Erb 2neu DNA Vaccines For Breast Cancer ImmunotherapyNational Cancer Institute1998–2002
Core--Flow Cytometry FacilityNational Cancer Institute1994–2002
Translational Oncology--Pathogenesis, Prognosis And Genetic SusceptibilityNational Cancer Institute2000
Immunology Of CLL I--Active Immunotherapy &Autologous Stem Cell TransplantationNational Cancer Institute1999
Chronic Lymphocytic Leukemia Research ConsortiumNational Cancer Institute1999
Regulation Of CD40L On Lymphocytes In Systemic Lupus ErythematosusNational Center For Research Resources1998–1999
Antibody V Gene Expression In B Cell CLLNational Cancer Institute1994–1998
Immunoglobulin And Gene ExpressionNational Center For Research Resources1996–1997
Effect Of N-Acetylcysteine On Lymphocyte Activation In Rheumatoid ArthritisNational Center For Research Resources1996–1997
ERBB 2/Neu DNA Vaccines For Breast Cancer ImmunotherapyNational Cancer Institute1996–1997
Erbb-2/Neu DNA Vaccines For Breast Cancer ImmunotherapyNational Cancer Institute1995–1997
Immunobiology Of AIDS LymphomasNational Cancer Institute1994–1997
Immunologic Aging And AutoimmunityNational Institute On Aging1992–1994
Mechanisms Of Aids-Associated LymphomagenesisNational Cancer Institute1991–1994
New Modalities For Active Immunotherapy Of MalignanciesNational Cancer Institute1992–1993
Novel Therapeutic Approaches In Hiv-Associated LymphomasNational Cancer Institute1991–1993
Antibody V Gene Expression In Human B Cell MalignanciesNational Cancer Institute1990–1993
Immunologic Aging And AutoimmunityNational Institute On Aging1991
Human Antibody Diversity In Health &AutoimmunityNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1990
Antibody V Gene Expression In Human B Cell MalignanciesNational Cancer Institute1989–1990
Isolation And Function Of Switch Variant Monoclonal AntibodiesNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1989
Bone Marrow In Immunologic Aging And AutoimmunityNational Institute On Aging1987–1989
Human Antibody Diversity In Health &AutoimmunityNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1986–1989
Multiparameter Fluorescence Activated Cell SorterNational Center For Research Resources1988